Real World Data Study Assessing The Persistency Of Xalacom And The Other Fixed Dose Combination Products, Duotrav And Ganfort, In The United Kingdom

Viatris

Status: Completed

Conditions: Glaucoma; Ocular Hypertension

Treatments: Drug: Ganfort; Drug: Duotrav; Drug: XALACOM

Study type: Observational

Funder types: Industry

Identifiers

NCT01206361

A6111145

Details and patient eligibility

About

The hypothesis is that there is no difference in persistency between Xalacom and the alternative fixed dose combination products (Duotrav and Ganfort) over a 12 month period.

Enrollment: 2,015 patients

Sex: All

Ages: 18 to 100 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients who had received a prescription for either Xalacom, Ganfort and DuoTrav
• Greater than 18 years old
• Diagnosed with glaucoma or ocular hypertension
• Registered at the primary care practice for > 12 months

Exclusion criteria

• None

Trial design

2,015 participants in 1 patient group

fixed dose prostaglandin combination

Treatment:

Drug: Ganfort

Drug: Duotrav

Drug: XALACOM